What is CervoMed Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. CervoMed's interest expense for the
three
months ended in Mar. 2024 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. CervoMed's Operating Income for the
three
months ended in Mar. 2024 was $ -2.60 Mil. CervoMed's Interest Expense for the
three
months ended in Mar. 2024 was $ 0.00 Mil.
CervoMed has no long-term debt (1).
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
CervoMed Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CervoMed (NAS:CRVO) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
CervoMed's Interest Expense for the
three
months ended in Mar. 2024 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Mar. 2024 was $-2.60 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2024 was $0.00 Mil.
CervoMed's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as
| CervoMed had no long-term debt (1). |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
CervoMed Inc has no debt.
CervoMed (CervoMed) Business Description
Traded in Other Exchanges
N/A
Address
20 Park Plaza, Suite 424, Boston, MA, USA, 02216
CervoMed Inc Formerly Diffusion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The company's product candidate is trans sodium crocetinate (TSC), which is used for the treatment of glioblastoma multiforme (GBM) and metastatic brain cancer. Geographically business activity of the firm functions through the region of the United States.
Executives
| Frank Zavrl |
director |
C/O PUMA BIOTECHNOLOGY INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024 |
| Sylvie Gregoire |
director, 10 percent owner |
940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451 |
| John William Tanner |
officer: Chief Financial Officer |
C/O EIP PHARMA, INC., 20 PARK PLAZA, SUITE 424, BOSTON MA 02116 |
| Kelly Blackburn |
officer: VP, Clinical Development |
C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121 |
| Marwan Sabbagh |
director |
C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
| John J Alam |
director, 10 percent owner, officer: CEO and President |
130 WAVERLY STREET, CAMBRIDGE MA 02139 |
| Jeffrey V. Poulton |
director |
300 THIRD STREET, CAMBRIDGE MA 02142 |
| Jill Davidson |
director |
300 EAST MAIN STREET, SUITE 101, CHARLOTTESVILLE VA 22902 |
| Raven Jaeger |
officer: Chief Regulatory Officer |
300 EAST MAIN STREET, SUITE 201, CHARLOTTESVILLE VA 22902 |
| Eric Francois |
director |
C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713 |
| Diana M Lanchoney |
director |
1317 CARLTON AVE, SUITE 200, CHARLOTTESVILLE VA 22902 |
| William Robert Elder |
officer: GC & Secretary |
1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902 |
| Cobuzzi Robert Joseph Jr. |
director |
C/O DIFFUSION PHARMACEUTICALS INC., 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902 |
| Christopher D Galloway |
officer: Chief Medical Officer |
1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902 |
| Jane H Hollingsworth |
director |
DIFFUSION PHARMACEUTICALS INC., 1317 CARLTON AVENUE, SUITE 200, CHARLOTTESVILLE VA 22902 |
CervoMed (CervoMed) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRVO has been successfully added to your 